Cite

HARVARD Citation

    Berman, G. et al. (2020). Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache. 60 (8), pp. 1734-1742. [Online]. 
  
Back to record